Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty
- 4 June 2013
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 158 (11) , 800-806
Abstract
Chinese translation The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA. Multicenter randomized, controlled trial with a noninferiority design based on a minimal clinically important difference of 2.0%. Randomization was electronically generated; patients were assigned to a treatment group through a Web-based program. Patients, physicians, study coordinators, health care team members, outcome adjudicators, and data analysts were blinded to interventions. (Current Controlled Trials: ISRCTN11902170) 12 tertiary care orthopedic referral centers in Canada. 778 patients who had elective unilateral THA between 2007 and 2010. After an initial 10 days of dalteparin prophylaxis after elective THA, patients were randomly assigned to 28 days of dalteparin (n = 400) or aspirin (n = 386). Symptomatic VTE confirmed by objective testing (primary efficacy outcome) and bleeding. Five of 398 patients (1.3%) randomly assigned to dalteparin and 1 of 380 (0.3%) randomly assigned to aspirin had VTE (absolute difference, 1.0 percentage point [95% CI, −0.5 to 2.5 percentage points]). Aspirin was noninferior (P < 0.001) but not superior (P = 0.22) to dalteparin. Clinically significant bleeding occurred in 5 patients (1.3%) receiving dalteparin and 2 (0.5%) receiving aspirin. The absolute between-group difference in a composite of all VTE and clinically significant bleeding events was 1.7 percentage points (CI, −0.3 to 3.8 percentage points; P = 0.091) in favor of aspirin. The study was halted prematurely because of difficulty with patient recruitment. Extended prophylaxis for 28 days with aspirin was noninferior to and as safe as dalteparin for the prevention of VTE after THA in patients who initially received dalteparin for 10 days. Given its low cost and greater convenience, aspirin may be considered a reasonable alternative for extended thromboprophylaxis after THA. Canadian Institutes of Health Research.Keywords
This publication has 28 references indexed in Scilit:
- The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacementThe Journal of Bone and Joint Surgery. British volume, 2011
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgeryCanadian Medical Association Journal, 2008
- Venous protocols, techniques, and interpretations of the upper and lower extremitiesRadiologic Clinics of North America, 2004
- Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 2002
- Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trialsThe Lancet, 2001
- Incidence and Time Course of Thromboembolic Outcomes Following Total Hip or Knee ArthroplastyArchives of internal medicine (1960), 1998
- Efficacy and Safety of Prolonged Thromboprophylaxis with a Low Molecular Weight Heparin (Dalteparin) after Total Hip Arthroplasty— The Danish Prolonged Prophylaxis (DaPP) StudyThrombosis Research, 1998
- Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1996
- Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin: Overview of Results of Randomized Trials in General, Orthopedic, and Urologic SurgeryJournal of Urology, 1989